olmesartan has been researched along with Body Weight in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (36.36) | 29.6817 |
| 2010's | 14 (63.64) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hsieh, YS; Kang, P; Kwon, S; Seol, GH; Shin, YK | 1 |
| Hirooka, Y; Nishihara, M; Takesue, K | 1 |
| Carbone, A; Cicero, AF; D'Angelo, A; Derosa, G; Fogari, E; Maffioli, P; Querci, F | 3 |
| Azushima, K; Kanaoka, T; Kobayashi, R; Maeda, A; Matsuda, M; Ohki, K; Ohsawa, M; Tamura, K; Tokita, Y; Tsurumi-Ikeya, Y; Umemura, S; Uneda, K; Wakui, H; Yamashita, A | 1 |
| Dong, YF; Ichijo, H; Kataoka, K; Kim-Mitsuyama, S; Matsuba, S; Ogawa, H; Tokutomi, Y; Yamamoto, E; Yamashita, T | 1 |
| Adachi, Y; Harada, M; Horiuchi, M; Kinoshita, H; Kishimoto, I; Kuwahara, K; Li, Y; Murray, M; Nakanishi, M; Nakao, K; Rong, X; Saito, Y | 1 |
| Ishihara, Y; Kohno, M; Kosaka, H; Mizukawa, M; Noma, T; Obayashi, A; Ohmori, K; Yoshida, J; Yukiiri, K | 1 |
| Ban, N; Endo, K; Kawana, H; Miyashita, Y; Nagayama, D; Ohira, M; Oyama, T; Saiki, A; Shirai, K; Yamaguchi, T | 1 |
| Bai, Y; Dejima, T; Hirawa, N; Horiuchi, M; Ichihara, N; Ishigami, T; Kobayashi, Y; Maeda, A; Masuda, S; Matsuda, M; Minamisawa, S; Mogi, M; Shigenaga, A; Tamura, K; Tanaka, Y; Toya, Y; Umemura, S; Wakui, H; Yabana, M | 1 |
| Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Fogari, E; Gravina, A; Maffioli, P; Mereu, R; Palumbo, I; Salvadeo, SA | 1 |
| Dellsperger, KC; DeMarco, VG; Gul, R; Habibi, J; Hayden, MR; Johnson, MS; Pulakat, L; Sowers, JR; Tilmon, RD; Whaley-Connell, AT; Winer, N | 1 |
| Aller, R; Castro, MJ; Conde, R; De Luis, DA; Gonzalez Sagrado, M; Izaola, O; Perez Castrillon, JL; Romero, E | 1 |
| Hitomi, H; Horiuchi, M; Hosomi, N; Kobori, H; Kohno, M; Matsumoto, M; Mogi, M; Nakano, D; Nishiyama, A; Pelisch, N; Sakamoto, H; Shimada, K; Ueno, M | 1 |
| Baba, M; Kojima, K; Sugimoto, K; Yasujima, M | 1 |
| Hara, T; Hayden, MR; Hitomi, H; Ichimura, A; Ito, S; Kaifu, K; Kawachi, H; Kiyomoto, H; Kobori, H; Kohno, M; Matsumoto, S; Nishijima, Y; Nishiyama, A; Ohsaki, H; Sofue, T; Sowers, JR; Urushihara, M; Whaley-Connell, A | 1 |
| Fukumoto, Y; Hosoya, M; Nakajima, S; Noda, K; Ohashi, J; Shimokawa, H | 1 |
| Arakawa, N; Fujimori, I; Inoue, T; Nakamura, H; Shimakawa, E; Shimizu, Y; Toyoshi, T; Yokoyama, T; Yoshigae, Y | 1 |
| Abe, Y; Baba, R; Fan, YY; Fujita, M; Hosomi, N; Kimura, S; Kohno, M; Miyatake, A; Nagai, Y; Nishiyama, A; Sun, GP | 1 |
| Abe, S; Ishihara, M; Ishizawa, K; Izawa, Y; Kanematsu, Y; Kawazoe, K; Motobayashi, Y; Ohnishi, H; Tamaki, T; Tsuchiya, K | 1 |
| Fujita, T; Horiuchi, M; Iwai, M; Iwanami, J; Li, JM; Min, LJ; Mogi, M; Sakata, A; Tsukuda, K | 1 |
6 trial(s) available for olmesartan and Body Weight
| Article | Year |
|---|---|
Evaluation of safety and efficacy of a fixed olmesartan/amlodipine combination therapy compared to single monotherapies.
Topics: Adipokines; Amlodipine; Blood Glucose; Blood Pressure; Body Mass Index; Body Weight; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypertension; Imidazoles; Inflammation; Insulin; Insulin Resistance; Interleukin-10; Interleukin-8; Lipids; Male; Middle Aged; Tetrazoles | 2013 |
Results from a 12 months, randomized, clinical trial comparing an olmesartan/amlodipine single pill combination to olmesartan and amlodipine monotherapies on blood pressure and inflammation.
Topics: Amlodipine; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Mass Index; Body Weight; Double-Blind Method; Drug Combinations; Female; Humans; Hypertension; Imidazoles; Inflammation; Insulin Resistance; Lipids; Male; Middle Aged; Tetrazoles | 2014 |
Effects of olmesartan, an angiotensin II receptor blocker, and amlodipine, a calcium channel blocker, on Cardio-Ankle Vascular Index (CAVI) in type 2 diabetic patients with hypertension.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Ankle; Antihypertensive Agents; Body Weight; Calcium Channel Blockers; Deoxyguanosine; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypertension; Imidazoles; Lipids; Male; Middle Aged; Tetrazoles | 2009 |
Differential effects of candesartan and olmesartan on adipose tissue activity biomarkers in type II diabetic hypertensive patients.
Topics: Adipose Tissue; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biomarkers; Biphenyl Compounds; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Female; Glycemic Index; Humans; Hypertension; Hypoglycemic Agents; Imidazoles; Insulin Resistance; Male; Middle Aged; Tetrazoles | 2010 |
Effects of olmesartan vs irbesartan on metabolic parameters and visfatin in hypertensive obese women.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biomarkers; Biphenyl Compounds; Blood Glucose; Blood Pressure; Body Mass Index; Body Weight; Cholesterol; Cytokines; Female; Humans; Hypertension; Imidazoles; Insulin; Irbesartan; Middle Aged; Nicotinamide Phosphoribosyltransferase; Obesity; Prospective Studies; Spain; Tetrazoles; Time Factors; Treatment Outcome; Triglycerides | 2010 |
Olmesartan/amlodipine combination versus olmesartan or amlodipine monotherapies on blood pressure and insulin resistance in a sample of hypertensive patients.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Body Mass Index; Body Weight; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypertension; Imidazoles; Insulin Resistance; Lipids; Male; Middle Aged; Tetrazoles; Treatment Outcome | 2013 |
16 other study(ies) available for olmesartan and Body Weight
| Article | Year |
|---|---|
Linalyl acetate prevents olmesartan-induced intestinal hypermotility mediated by interference of the sympathetic inhibitory pathway in hypertensive rat.
Topics: Animals; Blood Pressure; Body Weight; Cell Size; Epithelial Cells; Gastrointestinal Motility; Heart Rate; Hypertension; Imidazoles; Male; Monoterpenes; Neural Inhibition; Nitric Oxide; Nitrites; Nitroprusside; Norepinephrine; Rats, Sprague-Dawley; Sympathetic Nervous System; Tetrazoles; Vasodilation | 2018 |
Olmesartan combined with renal denervation reduces blood pressure in association with sympatho-inhibitory and aldosterone-reducing effects in hypertensive mice with chronic kidney disease.
Topics: Albuminuria; Aldosterone; Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Combined Modality Therapy; Heart; Hypertension; Imidazoles; Kidney; Male; Mice; Mice, Inbred ICR; Nephrectomy; Organ Size; Renal Insufficiency, Chronic; Renin-Angiotensin System; Sympathectomy; Sympathetic Nervous System; Tetrazoles | 2019 |
Effects of the Angiotensin receptor blocker olmesartan on adipocyte hypertrophy and function in mice with metabolic disorders.
Topics: Adipocytes; Angiotensin Receptor Antagonists; Animals; Blood Pressure; Body Weight; Disease Models, Animal; Gene Expression Regulation; Humans; Hypertrophy; Imidazoles; Interleukin-6; Metabolic Diseases; Mice; Obesity, Abdominal; Tetrazoles | 2014 |
Olmesartan prevents cardiovascular injury and hepatic steatosis in obesity and diabetes, accompanied by apoptosis signal regulating kinase-1 inhibition.
Topics: Adiponectin; Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Eating; Endothelium, Vascular; Fatty Liver; Fibrosis; Imidazoles; Insulin Resistance; Male; MAP Kinase Kinase Kinase 5; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; NADPH Oxidases; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Obesity; Reactive Oxygen Species; Signal Transduction; Tetrazoles; Transforming Growth Factor beta1 | 2008 |
Guanylyl cyclase-A inhibits angiotensin II type 2 receptor-mediated pro-hypertrophic signaling in the heart.
Topics: Angiotensin II Type 2 Receptor Blockers; Animals; Body Weight; Cardiomegaly; Collagen; Heart; Imidazoles; Immunoblotting; Male; Mice; Mice, Knockout; Myocardium; Organ Size; Pyridines; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Atrial Natriuretic Factor; Reverse Transcriptase Polymerase Chain Reaction; Tetrazoles; Vasoconstrictor Agents | 2009 |
Effects of combined olmesartan and pravastatin on glucose intolerance and cardiovascular remodeling in a metabolic-syndrome model.
Topics: Adiponectin; Adipose Tissue, White; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Glucose; Blood Pressure; Blotting, Western; Body Weight; Cardiovascular System; Drug Therapy, Combination; Eating; Glucose Intolerance; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imidazoles; Lipids; Male; Metabolic Syndrome; Nitric Oxide Synthase Type III; Oxidation-Reduction; Pravastatin; Rats; Rats, Inbred OLETF; RNA, Messenger; Superoxides; Tetrahydrofolate Dehydrogenase; Tetrazoles | 2009 |
Cardiac-specific activation of angiotensin II type 1 receptor-associated protein completely suppresses cardiac hypertrophy in chronic angiotensin II-infused mice.
Topics: Adaptor Proteins, Signal Transducing; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Body Weight; Cardiomegaly; Genotype; Heart Rate; Imidazoles; Male; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Mitogen-Activated Protein Kinase Kinases; Reverse Transcriptase Polymerase Chain Reaction; RNA; Tetrazoles | 2010 |
Comparative analysis of telmisartan and olmesartan on cardiac function in the transgenic (mRen2)27 rat.
Topics: Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Blood Pressure; Body Weight; Heart; Heart Function Tests; Hypertrophy, Left Ventricular; Imidazoles; Janus Kinase 2; Male; Myocardium; Myocytes, Cardiac; Oxidative Stress; Phosphorylation; Rats; Rats, Sprague-Dawley; Rats, Transgenic; Renin-Angiotensin System; Telemetry; Telmisartan; Tetrazoles | 2011 |
Blockade of AT1 receptors protects the blood-brain barrier and improves cognition in Dahl salt-sensitive hypertensive rats.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blood-Brain Barrier; Body Weight; Capillary Permeability; Cognition; Corpus Callosum; Hippocampus; Hypertension; Imidazoles; Immunohistochemistry; Male; Platelet Endothelial Cell Adhesion Molecule-1; Rats; Rats, Inbred Dahl; RNA, Messenger; Systole; Tetrazoles | 2011 |
Olmesartan ameliorates peripheral nerve dysfunction in Zucker diabetic fatty rats.
Topics: Adipokines; Animals; Blood Glucose; Blotting, Western; Body Weight; Diabetes Mellitus, Experimental; Fluorescent Antibody Technique; Ganglia, Spinal; Imidazoles; Insulin; Lipids; Male; Mitogen-Activated Protein Kinases; Peripheral Nerves; Phosphorylation; Rats; Rats, Zucker; Receptor, Insulin; Tetrazoles | 2011 |
Early treatment with olmesartan prevents juxtamedullary glomerular podocyte injury and the onset of microalbuminuria in type 2 diabetic rats.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Disease Models, Animal; Hydralazine; Hydrochlorothiazide; Imidazoles; Juxtaglomerular Apparatus; Male; Membrane Proteins; Podocytes; Rats; Rats, Inbred OLETF; Reserpine; Tetrazoles | 2012 |
Anti-atherogenic effects of the combination therapy with olmesartan and azelnidipine in diabetic apolipoprotein E-deficient mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Apolipoproteins E; Atherosclerosis; Azetidinecarboxylic Acid; Azo Compounds; Blood Pressure; Body Weight; Calcium Channel Blockers; Coronary Vessels; Diabetes Mellitus, Experimental; Dihydropyridines; Drug Therapy, Combination; Imidazoles; Macrophages; Male; Mice; Mice, Inbred C57BL; Models, Biological; Myocytes, Cardiac; Nitric Oxide Synthase Type III; Oxidative Stress; Phosphorylation; Systole; Tetrazoles | 2012 |
Pharmacological and pharmacokinetic study of olmesartan medoxomil in animal diabetic retinopathy models.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Area Under Curve; Benzimidazoles; Biphenyl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Disease Models, Animal; Dose-Response Relationship, Drug; Electroretinography; Glycated Hemoglobin; Heart Rate; Hypertension; Hypoxia; Imidazoles; Male; Olmesartan Medoxomil; Oxygen; Rats; Rats, Inbred SHR; Retinal Neovascularization; Tetrazoles | 2005 |
Augmentation of intrarenal angiotensin II levels in uninephrectomized aldosterone/salt-treated hypertensive rats; renoprotective effects of an ultrahigh dose of olmesartan.
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Body Weight; Collagen; Connective Tissue Growth Factor; Creatine; Hypertension; Imidazoles; Immediate-Early Proteins; Intercellular Signaling Peptides and Proteins; Kidney; Male; Nephrectomy; Organ Size; Peptidyl-Dipeptidase A; Proteinuria; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Sodium Chloride; Tetrazoles; Transforming Growth Factor beta | 2006 |
Effects of angiotensin II type 1 receptor blockade on the systemic blood nitric oxide dynamics in Nomega-nitro-L-arginine methyl ester-treated rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Electron Spin Resonance Spectroscopy; Endothelium, Vascular; Heart Rate; Hemodynamics; Hemoglobins; Hydralazine; Hypertension; Imidazoles; Male; NG-Nitroarginine Methyl Ester; Nitric Oxide; Rats; Rats, Sprague-Dawley; Tetrazoles | 2006 |
Inhibition of cognitive decline in mice fed a high-salt and cholesterol diet by the angiotensin receptor blocker, olmesartan.
Topics: Age Factors; Analysis of Variance; Angiotensin Receptor Antagonists; Animals; Avoidance Learning; Behavior, Animal; Blood Glucose; Blood Pressure; Body Weight; Brain; Cholesterol; Cognition Disorders; Gene Expression Regulation; Imidazoles; Male; Mice; Mice, Inbred C57BL; Sodium Chloride, Dietary; Superoxides; Tetrazoles; Ubiquitin-Conjugating Enzymes | 2007 |